Multi-Epitope Vaccines Designing and Diagnostics for Emerging Pathogens

Dear Colleagues,

Every day, the globe faces the problem of newly developing pathogens, which demand quick diagnosis and effective control. Currently, the COVID-19 and monkeypox viral pandemics are on the rise, along with infections that are becoming increasingly resistant to recognized cures and preventative measures. Precise epitope mapping is a powerful method for creating sensitive diagnostics tools by precisely identifying the antibody's binding location on a given pathogen's antigen. Additionally, it has been demonstrated that the application of epitope mapping techniques speeds up the production of safe and convenient immunoprophylactic treatments. To comprehend and manage newly developing infections and direct the development of vaccines and diagnostics, computational tools (big data analytics) for tracking the epidemic are now very effective. The development of vaccines and diagnostics is simultaneously ramped up while cost and time are reduced, thanks to immunoinformatic strategies based on artificial intelligence (AI) technologies. Furthermore, AI is employed in place of a significant number of experimental animals to assess the safety and allergenicity of the identified epitopes. A notable example of this is COVID-19, where the manufacturing of epitope-mapped vaccines and immunodiagnostics was started based on epitopes predicted by those in silico found building blocks when China first revealed the structure of the whole genome of the virus. Additionally, the epidemiological research of the virus's transmission and response to treatment obtained an enhanced understanding of how to handle the pandemic and stop its spreading. In order to meet the clinical demands brought on by the emergence of novel infectious diseases, we wish to consolidate the most recent developments in the epitope mapping tool and related artificial intelligence for the construction of potent vaccines, treatments, and diagnostic tools in this Research Topic. Reviews, original research, and other article forms that further these topics are appreciated. 

• Multi-epitope vaccines
• Reverse vacciniology
• Peptides vaccines
• Immunogen
• Subunit vaccines
• Cell mediated immunity
• Humoral immunity
• Nuclic acid vaccines 

Dr. Ajmal Khan
Dr. Sobia Halim
Prof. Dr. Ahmed Al-Harrasi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• precise epitope mapping
• infectious diseases
• diagnosis
• diagnostic tools
• vaccines
• pathogens